Aerocrine enters distribution agreement with Chest in Japan

SOLNA – February 11, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Chest M.I. Inc. Chest will market and sell NIOX MINO® in Japan.

Chest manufactures and sells a large range of products to measure lung function as well oxygen delivery systems for home use. The company which was founded in 1965 is one of the largest companies in its field with over 50% share of the Japanese market. Chest has an impeccable reputation and impressive market coverage with over 10 local sales offices. Chest will apply for market authorization of NIOX MINO in Japan and then proceed to product launch.

”Chest is an ideal partner for marketing and sales of our product in Japan”, says Paul de Potocki, CEO of Aerocrine. ”The company has established relations and years of experience from selling medical devices to our prime target groups. Chest has also shown an impressive knowledge and enthusiasm for our product and method of inflammatory control.”

Eight million people suffers from asthma in Japan and the disease causes around 3000 deaths yearly, primarily due to inferior disease control. NIOX MINO is a handheld device that in a couple of minutes gauges the inflammation in the airways, the underlying cause of asthma. Treatment of asthma focuses primarily on keeping the inflammation under control, which leads to fewer symptoms and less acute asthma exacerbations.


For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82